Our product range is developed directly from our expertise in preparing reagents for application in infectious disease research and development, including use in the manufacturing of immunoassays in the IVD sector, and for vaccine research in the pharmaceutical sector.
The Native Antigen Company produces infectious disease antigens from a range of established and emerging viral, bacterial and protozoal diseases. We provide both native and recombinant antigens produced using our mammalian expression system. Our antigens are suitable for use in vaccine R&D, as components for serological based diagnostic assays and for fundamental research into infectious diseases. We have decades of experience in providing bulk and customised formats for industry.
Our immunoassays for Zika virus are the most specific and sensitive available on the market. We have assays to detect the serological response to infection, and also to measure levels of Zika NS1 protein during infection. Further immunoassays are in development, so please check back regularly for updates.
Human cell surface receptors (CSRs) are as key proteins for the development of novel therapeutics. To support research in this area, we have produced a panel of recombinant human CSRs that are known to mediate virus entry. In many cases, we also provide the viral proteins that bind the corresponding CSR for molecular interaction studies.